Cara Therapeutics reported $182.24M in Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Acadia Pharmaceuticals ACAD:US USD 587.81M 14.68M
Acelrx Pharmaceuticals ACRX:US USD 48.31M 7.82M
Cara Therapeutics CARA:US USD 182.24M 31.27M
Chugai Pharma 4519:JP JPY 1.87T 168.94B
Depomed DEPO:US USD 413.91M 90.57M
Endo International Ordinary Shares ENDP:US USD 6.01B 355.8M
Halozyme Therapeutics HALO:US USD 1.84B 23.03M
Horizon Pharma HZNP:US USD 9.11B 86.75M
Neurocrine Biosciences NBIX:US USD 2.37B 225.3M
Pacira Pharmaceuticals PCRX:US USD 1.68B 53.16M
Pain Therapeutics PTIE:US USD 234.83M 27.55M
Revance Therapeutics RVNC:US USD 581.9M 129.69M
Supernus Pharmaceuticals SUPN:US USD 1.7B 9.38M
Teva Pharmaceutical Industries TEVA:US USD 44.01B 246M
Vanda Pharmaceuticals VNDA:US USD 634.25M 12.46M